# Clinical Benefit of Topoisomerase Downregulation

> **NCT00250094** · PHASE1 · COMPLETED · sponsor: **New Mexico Cancer Research Alliance** · enrollment: 15 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Topotecan and VP16

## Key facts

- **NCT ID:** NCT00250094
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2005-06
- **Final completion:** 2006-03
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2011-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00250094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00250094, "Clinical Benefit of Topoisomerase Downregulation". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00250094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*